Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
Open Access
- 4 November 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 17 (12), 1653-1660
- https://doi.org/10.1016/s1470-2045(16)30562-9
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsiesNature Medicine, 2012
- RET, ROS1 and ALK fusions in lung cancerNature Medicine, 2012
- KIF5B-RET fusions in lung adenocarcinomaNature Medicine, 2012
- A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencingGenome Research, 2011
- Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor GrowthMolecular Cancer Therapeutics, 2011
- The Effects of Four Different Tyrosine Kinase Inhibitors on Medullary and Papillary Thyroid Cancer CellsJournal of Clinical Endocrinology & Metabolism, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004